Aptose Biosciences (APTO) announced that its board of directors has approved, subject to required regulatory and stock exchange approvals, a plan to consolidate all of its outstanding common shares on the basis of 1 Common Share for every 30 Common Shares currently outstanding. The Company expects the Reverse Share Split to restore compliance with the minimum bid price requirement set out in Nasdaq Listing Rule 5550(a)(2) and to ensure the Company continues to have access to a wide range of investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APTO:
- Biotech Alert: Searches spiking for these stocks today
- Aptose Biosciences Secures $25M Share Purchase Agreement
- Aptose Biosciences files to sell 12.03M shares of common stock for holders
- Aptose Biosciences Establishes $25M Equity Facility
- Promising Results from Aptose Biosciences’ TUSCANY Trial Boost Joseph Pantginis’ Buy Rating